SREBP1a is back at the center of the PXR story.

More than ten years ago, our 2015 Archives of Toxicology study identified SREBP1a induction as a key mechanism linking PXR activation to the SREBP1-dependent lipogenic pathway in human hepatic cells.

A new Archives of Toxicology study now provides independent in vivo support for that axis.

The key signal is clear:

Atorvastatin induced hepatic Srebf1a in Pxr+/+ mice.
In Pxr−/− mice, this response disappeared.

That is the genetic point.

PCN adds the biological weight. As the prototypical mouse PXR agonist, PCN also induced Srebf1a in wild-type liver and activated nuclear SREBP1.

Together, these findings place SREBP1a within the PXR-shaped hepatic transcriptional state space.

This is not just another lipid gene response.

It is independent in vivo support for a mechanism that has been central to srebp1a.com from the beginning: the PXR–SREBP1a axis.

The timing is remarkable.

Recent work has already pushed AKR1B10 beyond marker status and strengthened it as a functional lipogenic stress-state node. Now, SREBP1a also receives independent support as a second molecular anchor of a detoxification–lipogenic hepatic state.

This does not prove Detoxification State Fixation as a whole.

But it changes the weight of interpretation.

SREBP1a is no longer "only" an early human hepatic cell observation.

More than ten years later, it is independently supported in vivo — downstream of PXR.

References

Nabil, H. et al. Atorvastatin regulates hepatic transcriptome PXR dependently but distinct from pregnenolone 16α-carbonitrile and does not induce PXR-mediated liver steatosis. Archives of Toxicology 100, 1443-1463 (2026). https://doi.org/10.1007/s00204-025-04280-0

Bitter, A. et al. Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms. Archives of Toxicology 89, 2089-2103 (2015). https://doi.org/10.1007/s00204-014-1348-x